Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Switzerland

Our Life Sciences & Healthcare team consists of specialised attorneys who will advise and represent you in all legal matters competently and tailored to the special needs of your company. 

With more than 300 lawyers specialising in the Life Sciences & Healthcare sector worldwide and the support of the Life Sciences Asia Pacific Network (LAN), we at CMS are very familiar with the economic, commercial and legal needs of our clients in those industries.

Reputation

We have been working successfully for many years with leading companies in the Life Sciences sector in the fields of pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs and cosmetics. These include the world’s most important pharmaceutical companies and the world’s leading medical device companies. In the Healthcare sector, we advise and represent all relevant medical service providers (hospitals, HMOs, nursing homes, laboratories, physicians, pharmacists, etc.) and their associations.

Comprehensive advice and representation

We regularly advise our Life Sciences clients on their day-to-day business, for example in:

  • Research and development (particularly in clinical trials)
  • Patent enforcement
  • Regulatory authorisations
  • Advertising and distribution issues
  • Pricing strategies and reimbursements under social security law
  • Compliance
  • Data protection

We support our Healthcare clients in particular in the areas of:

  • Social security regulatory authorisations
  • Professional law
  • Data protection
  • Tariff negotiations and tariff settings
  • Planning (hospital planning, planning of highly-specialised medicine)
  • Liability issues and compliance

Whether you require professional support in the area of contracts, strategic agreements or in competition and antitrust law, or an expert opinion, are planning a corporate transaction or seek to engage in legal proceedings or are affected by legal, administrative or criminal proceedings, we would be delighted to assist you.

Industry knowledge

Many of our experts have worked in Life Sciences & Healthcare companies prior to joining CMS, gaining extensive knowledge in pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs, cosmetics and medical services. Through our active membership in the most important industry associations and our participation in the legislative process, we contribute to shaping the legal and regulatory framework for the Life Sciences & Healthcare sector.


Find out more in our Life Sciences & Healthcare brochure

Read more Read less

'Due to very good networking', CMS 'can provide know-how in a variety of matters', especially at a multi-jurisdictional level. Regulatory, compliance, financial benefits and pricing advice, as well as the negotiation of agreements and representation in court form the main areas of expertise.

The Legal 500, Healthcare and life sciences, Switzerland, 2019
28 August 2020
Life Sci­ences & Health­care Prac­tice Group Switzer­land
Your spe­cial­ists in the field of Life Sci­ences & Health­care Our Life Sci­ences & Health­care team con­sists of spe­cial­ised at­tor­neys who will ad­vise and rep­res­ent you in all leg­al mat­ters com­pet­ently and...

Feed

Show only
06 April 2021
EU is­sues draft of Di­git­al Mar­kets Act aimed at cre­at­ing a new and fair...
The European Com­mis­sion has pub­lished a draft pro­pos­al for a new com­pet­i­tion law frame­work for large on­line plat­forms, called the Di­git­al Mar­kets Act (DMA). The Com­mis­sion pro­posed the DMA due to the...
23 March 2021
The En­larged Board of the European Pat­ent Of­fice has giv­en a mo­ment­ous...
The En­larged Board of the European Pat­ent Of­fice heard or­al ar­gu­ments in Ju­ly 2020 con­cern­ing pat­entab­il­ity of a com­puter soft­ware in­ven­tion.  This rare event was video streamed to over 1600 pat­ent stake­hold­ers...
05 March 2021
New EPO Guidelines on an­ti­body claims provide fur­ther clar­ity for ap­plic­ants
In­tro­duc­tion The EPO has now pub­lished their re­vised Guidelines for Ex­am­in­a­tion 2021[1] which con­tain new sec­tions de­tail­ing EPO prac­tice in re­la­tion to an­ti­bod­ies for the first time, en­ter­ing in­to force...
24 February 2021
COV­ID and ViCo: EPO re­fer­ral to the En­larged Board of Ap­peal
In the last year, the COV­ID-19 pan­dem­ic has res­ul­ted in a large pro­por­tion of the leg­al sec­tor trans­ition­ing to a ‘work from home’ ar­range­ment, with meet­ings tak­ing place re­motely. Non-es­sen­tial travel...
16 February 2021
Fight­ing poor med­ic­a­tion ad­her­ence in the European Uni­on: The Grav­it­ate-Health...
Nowadays, European cit­izens can ob­tain a great amount of in­form­a­tion (on­line and off­line) about any medi­cine. However, this in­form­a­tion is in many cases un­re­li­able and dif­fi­cult to un­der­stand, en­cour­aging...
01 February 2021
Switzer­land launches re­vi­sion of Fed­er­al Act on Pat­ents
On Oc­to­ber 14, 2020, the Fed­er­al Coun­cil opened a con­sulta­tion pro­ced­ure for the par­tial re­vi­sion of the Swiss Fed­er­al Act on Pat­ents for In­ven­tions (FPA). Ac­cord­ing to the new draft re­vi­sion, the Swiss...
18 January 2021
Im­pos­ing vir­tu­al ar­bit­ra­tion hear­ings in times of COV­ID-19: The Swiss per­spect­ive
On 6 Ju­ly 2020 the Swiss Fed­er­al Tribunal has is­sued a de­cision in which it has held that the COV­ID-19 pan­dem­ic does not serve as a suf­fi­cient jus­ti­fic­a­tion to im­pose vir­tu­al hear­ings in state court...
13 January 2021
EU­'s Por­tuguese pres­id­ency re­leases new draft of ePri­vacy Reg­u­la­tion
On 5 Janu­ary 2021, the Coun­cil of the EU – with Por­tugal serving as the Pres­id­ent-in-Of­fice – re­leased a new draft ver­sion of the ePri­vacy Reg­u­la­tion, which is meant to re­place the ePri­vacy Dir­ect­ive...
16 December 2020
EU Com­mis­sion pub­lishes pro­posed Data Gov­ernance Reg­u­la­tion
On 25 Novem­ber 2020 the European Com­mis­sion pro­posed new rules on data gov­ernance – a pro­posed Data Gov­ernance Reg­u­la­tion, which is the first of a set of meas­ures an­nounced in the 2020 European strategy...
15 December 2020
Five years after Hua­wei ZTE FRAND li­cens­ing ob­lig­a­tions again be­fore the...
On 26 Novem­ber 2020, the Düs­sel­dorf Re­gion­al Court an­nounced that it would sus­pend a pat­ent in­fringe­ment pro­ceed­ing and refer key ques­tions on com­puls­ory li­cens­ing of stand­ard es­sen­tial pat­ents (SEP)...
03 December 2020
With the in­tro­duc­tion of a new Phar­ma­ceut­ic­al Strategy for Europe, the...
New Phar­ma­ceut­ic­al Strategy to be a corner­stone of the European Health Uni­on The new Phar­ma­ceut­ic­al Strategy for Europe, an­nounced by the EU Com­mis­sion on 25 Novem­ber, is ex­pec­ted to be­come a main pil­lar...
01 December 2020
EPO pri­or­ity claim en­ti­tle­ment – the “same ap­plic­ants” ap­proach up­held
In a Press Com­mu­niqué dated 6 Novem­ber 2020, the EPO sum­mar­ises the Tech­nic­al Board of Ap­peal 3.3.08 writ­ten de­cision re­cently is­sued in case T 844/18 con­firm­ing the re­voc­a­tion of a pat­ent re­lated to...